The pharmaceutical company reported third-quarter earnings and sales that beat analysts’ expectations, boosted by ...
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...
Sanofi SAN-0.92%decrease; red down pointing triangle is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company ...
Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...
PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...
Oct 25 (Reuters) - French drug maker Sanofi (SASY.PA), opens new tab on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than ...
Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...
PARIS (Reuters) -Sanofi on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R), French ...
Sanofi pitched today’s announcement in the context of its move last month to pay Orano Med and its partner RadioMedix 100 million euros upfront and commit up to 220 million euros in sales ...
PARIS, October 17, 2024--(BUSINESS WIRE)--Regulatory News: Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology ...
(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.